Genmab — Juni 2017
-
Seattle Genetics Disconti
nues Phase 3 Trial of Vadastuximab Talirine in Frontline Acute Myeloid Leukemia http://investor.seagen.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2281531 -
Haha børsen ta jer sammen!!! http://penge.borsen.dk/artikel/1/346906/aktier_flsmidth_og_genmab_styrer_c20_mod_rekord.html
-
dara/pom/dex godkendelse var ventet. tisotumab var iflg. Sukkeralf og Solsen ikke "run-away data". Så kursudviklingen er vel som man kunne forvente!
-
bare fordi en udenlandsk investor sælger ud pga upside risc, så skal vi nu nok få stigningerne hen ad vejen. Nu skal vi bare se lidt stigning omsætningen, og så skinner realiteterne igennem
-
Mit bud: Bare vent til vi nærmer os kl 17. Så skal den den nok fise lidt i vejret igen.
-
Hvorfor så meget kortsigtet kurssnak? Casen udbygges fra måned til måned.
-
enig Helge.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
